Fact: As of mid-2026 data points, TRVI has demonstrated strong multi-year appreciation, with 1-year returns around 179%, 3-year around 722%, and 5-year around 868-903%, significantly outperforming the S&P 500 over those periods.
Interpretation: This performance reflects market enthusiasm for clinical progress in its cough programs and recent financing success, though biotech stocks are volatile and past returns do not predict future results.
Uncertainty: Short-term fluctuations (e.g., recent weekly gains of ~10-11%) may be driven by news flow or sentiment rather than fundamentals.
| Period | TRVI Return | S&P 500 Comparison |
|---|---|---|
| YTD (approx. mid-2026) | ~52% | ~9% |
| 1-Year | ~179% | ~18% |
| 3-Year | ~722% | ~65% |
| 5-Year | ~868-903% | ~72% |
Sources: Yahoo Finance, Simply Wall St, MarketBeat (data as of ~July 2026; Yahoo Finance, Simply Wall St)
Fact: Trevi is pre-revenue (total revenue $0 across reported periods). Annual net losses have ranged from ~$29M (2022-2023) to ~$43-48M (2024-2025), with TTM net loss ~$46M. Operating expenses ~$30-53M annually, primarily R&D.
Fact: Cash position strengthened significantly: Ended 2025 with $188.3M in cash, equivalents, and marketable securities (runway into 2028 at the time). Q1 2026: $171.8M; followed by April 2026 equity offering raising ~$162M net, extending runway into 2030.
| Metric | 2022 | 2023 | 2024 | 2025 | TTM / Q1 2026 Notes |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $29.9M | $33.9M | $51.5M | $49.3M | ~$52.8M TTM |
| Net Income (Loss) | -$29.2M | -$29.1M | -$47.9M | -$42.8M | -$45.6M TTM; Q1 2026: -$13.2M |
| Basic EPS | -$0.45 | -$0.29 | -$0.47 | -$0.32 | -$0.32 |
| Cash & Marketable Securities (year-end) | N/A | N/A | ~$108M | $188.3M | Q1 2026: $171.8M (pre-offering) |
Sources: Yahoo Finance financials, Company IR releases (Q1 2026 earnings May 2026, YE 2025 March 2026; Yahoo Finance, IR Site)
Fact: Consensus rating is Strong Buy / Buy across 7-11 analysts (recent coverage). Average 12-month price target ranges from ~$21-$25 (high $30, low $16-$20), implying substantial upside from mid-2026 levels per analyst models.
| Source | Consensus | Avg Target | # Analysts | Range |
|---|---|---|---|---|
| TipRanks | Strong Buy | $24.43-$24.86 | 7 | $20-$30 |
| MarketBeat | Buy | $22.67 | 11 | $16-$30 |
| Marketscreener | Buy | $23.90 | 10 | $20-$30 |
| Others (Zacks, etc.) | Buy | ~$23-25 | 10-17 | $16-$30 |
Interpretation: Analysts view the Haduvio pipeline (Phase 2b/3 cough trials) and cash runway positively, citing potential in underserved chronic cough markets.
Uncertainty: Targets are model-based projections; actual outcomes depend on clinical data, regulatory approvals, and commercialization success (high failure risk in biotech).
Sources: TipRanks, MarketBeat, CNN Markets, Marketscreener (as of ~July 2026; TipRanks, MarketBeat)
Fact: As a clinical-stage company with no approved or commercialized products, Trevi has no meaningful revenue-generating customers. Any future customers would be patients, physicians, or payers in respiratory/pulmonology and dermatology (pruritus) markets upon potential approval.
Interpretation: Focus remains on clinical development rather than sales; partnerships (e.g., licensing) could emerge later.
CSIMarket (confirms pre-revenue status)
Fact: Direct competitors are limited due to niche focus on chronic cough (IPF/RCC); broader peers in biotech/pharma (respiratory, neurology, or mid-cap development-stage) include those compared by analysts.
| Competitor | Ticker | Key Overlap/Notes | Market Cap Context |
|---|---|---|---|
| Cytokinetics | CYTK | Cardiac/respiratory focus; larger losses | Mid-cap |
| Nuvalent | NUVL | Oncology/biotech development | Mid-cap |
| Kymera Therapeutics | KYMR | Targeted protein degradation; similar stage risks | Mid-cap |
| ImmunityBio | IBRX | Immuno-oncology; high volatility | Mid-cap |
| Praxis Precision Medicines | PRAX | Neurology/precision med | Smaller |
Interpretation: TRVI often compares favorably to peers on analyst ratings, institutional ownership (~96%), and insider holdings (~18%), with lower net losses relative to some.
Uncertainty: Exact competitive landscape depends on trial readouts; no approved nalbuphine ER competitors for these indications currently.
Sources: MarketBeat competitor analysis (MarketBeat)
Fact: Founded/incorporated 2011, headquartered in New Haven, CT (34 employees). Develops Haduvio, oral extended-release nalbuphine (licensed from Keenova Therapeutics plc; prior Endo agreement noted historically). Pipeline targets chronic cough in IPF/non-IPF ILD and refractory chronic cough (Phase 2b/3 and Phase 2 programs ongoing as of 2026).
Fact: Recent milestones: Q1 2026 earnings (May 2026), April 2026 equity raise, multiple conference participations (ATS, BIO, ERS Cough Conference 2026), shareholder approvals for governance changes (June 2026).
For more information: Visit Official IR Site, Yahoo Finance, or SEC filings. This is not investment advice; data subject to change.